Mirada Medical sign agreement with Moffitt Cancer Center to develop new technologies for Radiotherapy Planning

October 27, 2010

Oxford, UK, Philadelphia, PA and Tampa, FL: Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that they have signed an agreement with Moffitt Cancer Center, Tampa, FL, one of the USA’s top centers for cancer treatment and oncology research.

The initial agreement allows the Oxford UK based company to evaluate and understand the Moffitt technology, and to potentially develop clinical applications which will encapsulate and build upon the anatomical atlases which have been developed by Dr S. Finkelstein, et al. Dr Finkelstein’s sarcoma atlas has been recognized by the Radiation Therapy Oncology Group (RTOG). The agreement extends to other anatomical regions, including the liver. Prototypes of the combined technology will be on show the ASTRO meeting (San Diego 31st October to 4th November, booth ##1813) said Mirada Medical, though the company pointed out that these developments are early stage and not currently available for sale in the USA or elsewhere.

Commenting on the joint development agreement, the Chair of the Moffitt Radiation Oncology Department, Dr Craig Stevens, said: “We are very excited about the opportunity to work with Mirada Medical. Their expertise and ours complement extremely well. We look forward to a long productive relationship.”

Ray Carpenter, Senior Licensing Manager at Moffitt Cancer Center, commented: “We are very pleased that, through this agreement, we begin a collaboration with an internationally accomplished company, Mirada Medical, to help develop the important research discovered here at Moffitt into valuable tools useful for the prevention and cure of cancer.”  

Hugh Bettesworth, CEO of Mirada Medical, said: “Mirada Medical’s philosophy is to ensure that the latest and most effective information technologies are available to the widest possible user base within the clinical community. We firmly believe that to do this, we need to innovate within our own company, but also be prepared to work with innovators working in clinical research elsewhere. The fact that something is or is not invented here is not our prime concern. Our mission is to discover the leading technologies and make these available to our growing user base. I expect our collaboration with Moffitt Cancer Center to provide a perfect example of this.”


For more information, please contact:

Mirada Medical

Europe: Hugh Bettesworth, CEO                                                tel:+44 (0) 1865 811172

US: Joan Washburn                                                                   tel: +1 865 696 7809

M:Communications

Mary-Jane Elliott / Emma Thompson                                          tel: +44 (0)20 7920 2345

Healthcare@mcomgroup.com

About Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center  is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.

About Mirada Medical

Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with advanced software applications for the quantification of images which are typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.